ALCAM and cancer: Consistent with this finding, CD166/ALCAM was previously found to be upregulated after genetic deletion of RAGE in the context of tissue inflammation driven by RAGE-ligands [200] and associated with tumor spread and recurrence in human cancers [201,202], including PDAC [202].